In a filing, Travere Therapeutics Inc revealed its Officer Peter Heerma acquired Company’s shares for reported $0.1 million on Feb 03 ’25. In the deal valued at $20.12 per share,5,166 shares were bought.
Then, Christopher Cline bought 5,192 shares, generating $104,457 in total proceeds.
Before that, Sandra Calvin bought 3,348 shares. Travere Therapeutics Inc shares valued at $67,358 were divested by the Officer at a price of $20.12 per share.
Cantor Fitzgerald initiated its Travere Therapeutics Inc [TVTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in late October from “an Equal weight” to “an Overweight”. Scotiabank began covering TVTX with “Sector outperform” recommendation on October 16, 2024. Guggenheim revised its rating on September 09, 2024. It rated TVTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TVTX
On Monday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock fall -1.17% to $20.22. Over the last five days, the stock has gained 0.45%. Travere Therapeutics Inc shares have risen nearly 16.07% since the year began. Nevertheless, the stocks have risen 126.43% over the past one year. While a 52-week high of $21.56 was reached on 01/24/25, a 52-week low of $5.12 was recorded on 01/14/25. SMA at 50 days reached $18.64, while 200 days put it at $12.74.
Levels Of Support And Resistance For TVTX Stock
The 24-hour chart illustrates a support level at 19.74, which if violated will result in even more drops to 19.25. On the upside, there is a resistance level at 20.64. A further resistance level may holdings at 21.05. The Relative Strength Index (RSI) on the 14-day chart is 56.52, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.90, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 28.15%. Stochastics %K at 79.34% indicates the stock is a holding.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2025-01-15, growing by 2.17 million shares to a total of 9.58 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 7.41 million shares. There was a rise of 22.67%, which implies that there is a positive sentiment for the stock.
